president united states george w bush signed food drug administration amendments act fdaaa september law reviewed expanded reaffirmed several existing pieces legislation regulating fda changes allow fda perform comprehensive reviews potential new drugs sponsored reps joe barton frank pallone passed unanimously fdaaa extended authority levy fees companies applying approval drugs expanded clinical trial guidelines pediatric drugs created priority review voucher program amongst items title amends federal food drug cosmetic act include postmarketing safety activities review drug application included developing using improved adverse event data collection systems improved analytical tools assess potential safety problems conducting screenings adverse event reporting system database reporting new safety concerns also reauthorizes prescription drug user fee act pfuda first enacted allow fda collect application fees pharmaceutical companies applying approval drug since reauthorized three times first recently passage fdaaa purpose fees provide resources fda help effectively review potential new recent reauthorization expand previous policy aims broaden upgrade drug safety program allocate resources television advertising theoretically allow fda efficiently review approve safe effective new drugs requires fda authority secretary health human services provide partial refund applicants user fees application withdrawn without waiver filing sets forth special rules positron emission tomography drugs including subjecting applicant drug application pet drug onesixth annual prescription drug establishment fee exempts approved drugs biological products designated rare disease orphan drugs product establishment fees certain requirements met including drug ownedlicensed marketed company gross worldwide revenues fall certain title ii given short title medical device user fee amendments mdufa defines terms relating fees medical devices notice defined notice supplement approved application limited request make modifications manufacturing procedures methods affecting safety effectiveness device makes changes medical device fees including establishing fee notice request classification information periodic reporting class iii device extends authority accredited people third parties review premarket reports devices make recommendations fda regarding classification devices requires establishment foreign country engaged manufacturing processing drug device imported us annually register title iii requires applications humanitarian device exemption application premarket approval medical device product development protocol medical device include available description pediatric subpopulations suffer disease device intended number affected pediatric patients requires fda submit annual report congressional committees includes number devices approved preceding year pediatric subpopulation suffers disease number approved devices labeled use pediatric patients number feeexempt devices approved review time approved device authorizes fda determine adult data medical devices may used support claims effectiveness pediatric populations course disease effects device sufficiently similar adults pediatric patients excludes person granted humanitarian device exemption prohibition selling device amount exceeds research development fabrication distribution costs device intended treat diagnose disease condition occurs pediatric patients device approved pediatric patients prior enactment act number devices distributed exceed annual distribution number specified secretary request exemption submitted october title iv requires applicant seeking defer submission pediatric assessments safety effectiveness new drug biological product submit fda timeline completion pediatric studies also sets forth annual reporting requirements applicant following approval deferral requires applicant seeking waiver pediatric assessment submission requirements grounds pediatric formulation developed submit documentation detailing pediatric formulation developed also authorizes fda require submission pediatric assessment secretary finds adequate pediatric labeling could confer benefit pediatric patients absence adequate pediatric labeling could pose significant risk pediatric title v short title best pharmaceuticals children act amends federal food drug cosmetic act revise provisions regarding market exclusivity pediatric drug studies new already approved drugs including change definition pediatric studies authorize secretary include preclinical studies require studies completed using appropriate formulations age group study requested prohibit fda extending period market exclusivity later nine months prior expiration period requires applicant agree request pediatric study submit secretary reasons pediatric formulations developed requires applicant agrees request provide secretary postmarketing adverse event reports regarding drug directs fda publish notice identifying drug pediatric formulation developed studied found safe effective pediatric population pediatric formulation introduced onto market within one year determination regarding market exclusivity utilize internal review committee review written requests pediatric studies issued track make publicly available information pediatric studies conducted order labeling product include information results study statement pediatric study demonstrate drug safe effective pediatric populations ensure adverse event reports received drug referred office pediatric therapeutics prescribes actions fda take pediatric studies completed continuing need information relating use drug pediatric population requires pediatric subcommittee oncologic drugs advisory committee provide recommendations internal review committee reviews pediatric research requests respect treatment pediatric pediatric trials network serves mechanism many studies offpatent drugs performed keeping bpca objective ensuring accurate drug labeling children title vi establishes reaganudall foundation food drug administration nonprofit corporation advance mission fda modernize product development accelerate innovation enhance product safety requires foundation identify unmet needs development manufacture evaluation safety effectiveness products establish goals priorities identify federal research development programs minimize duplication award grants scientists entities efficiently effectively advance goals priorities provide objective clinical scientific information fda federal agencies requires fda establish office chief scientist oversee coordinate ensure quality regulatory focus fda intramural research programs track coordinate intramural research awards made fda center sciencebased office develop advocate budget support intramural research develop peer review process intramural research evaluated identify solicit intramural research proposals across fda develop additional postmarketing safety performance title vii places limits serve fda advisory committee directs fda implement strategies effective outreach potential members advisory committees review expertise financial disclosure report individual considering appointment advisory committee prohibits member advisory committee participating respect matter member financial interest unless member granted waiver order afford advisory committee essential expertise number waivers limited decreases percentage committee members several title viii regard amends public health service act require fda acting director nih expand clinical trials registry data bank requires director ensure data bank made publicly available internet requires fda ensure data bank includes links results information clinical trials form primary basis efficacy claim conducted drug device involved approved title ix prohibits responsible person introducing interstate commerce new drug person violation requirement related postapproval clinical trials labeling changes authorizes fda require responsible person drug conduct postapproval study clinical trial drug assess known serious risk signals serious risk identify unexpected serious risk require postapproval study clinical trial already approved drug secretary becomes aware new safety information issue order directing responsible person holder approved application make labeling change address new safety information prohibits person introducing interstate commerce new drug biological product risk evaluation mitigation strategy required person fails maintain compliance requirements strategy requires proposed risk evaluation management strategy include timetable assessment strategy allows fda require strategy include additional elements including distribution patient medication guide patient package insert communication plan health care providers assurances safe use establishes drug safety oversight board authorizes fda require submission tv advertisement drug review broadcast make recommendations respect information included label drug statements inclusion advertisements require changes advertisements require inclusion advertisements certain disclosures serious risk listed labeling drug requires fda issue special guidance clinical trials antibiotics prohibits interstate commerce food approved drug licensed biological product certain drugs biological products added unless drug biological product marketed food prior approval licensure clinical investigation fda approved use drug biological product food use drug biological product enhance safety preservation food intended biological therapeutic effects use conformity specified regulations requires fda develop standards secure drug supply chain counterfeit diverted substandard adulterated misbranded expired drugs prioritize develop standards identification validation prescription drugs develop standardized numerical identifier prescription drugs expand resources facilities securing drug supply chain requires advisory committee risk communication regularly perform comprehensive review types risk information provided website recommend ways fda work outside entities help facilitate communication risk requires certain information related new drug application published fdas website including documents related review application summary conclusions reviewing disciplines drug stipulates scientific review application considered work reviewer prohibits altering work management reviewer final directs fda publish update quarterly complete list authorized generic drugs fdas title x requires fda work companies professional associations organizations ongoing recall food regulated fda collect aggregate information use existing networks enhance quality speed public communication post information regarding recalled food fdas website single location requires fda work states assist improving safety food requires responsible person determines article food reportable food submit report fda within hours investigate cause adulteration adulteration may originated responsible person requires fda immediately notify secretary homeland security fda believes food reported registry may deliberately adulterated requires fda produce report environmental risks associated genetically engineered seafood products sets forth reporting requirements respect food products regulated title xi requires fda identify periodically update clinically susceptible concentrations specific values characterize bacteria clinically susceptible intermediate resistant drug tested directs fda convene public meeting regarding infectious diseases potentially qualify available grants contracts orphan drug act incentives development amends orphan drug act reauthorize appropriations grants contracts defray costs testing development drugs medical devices medical foods rare diseases allows applicant nonracemic drug containing active ingredient single enantiomer contained racemic drug approved another application elect single enantiomer considered active ingredient contained approved racemic drug certain circumstances requires hhs secretary enter contract institute medicine conduct study assess overall safety quality genetic tests prepare report includes recommendations improve federal oversight regulation genetic title xi also created priority review voucher program requires fda award transferable priority review voucher sponsor tropical disease product application upon approval secretary application establish priority review user fee program act tropical diseases covered program incentivize development neglected tropical diseases expanded include rare pediatric conditions priority review vouchers awarded